Study type

Study type

Non-interventional study

Scope of the study

Drug utilisation
Effectiveness study (incl. comparative)
Safety study (incl. comparative)
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Retrospective observational study
Study drug and medical condition

Name of medicine

PAXLOVID

Study drug International non-proprietary name (INN) or common name

NIRMATRELVIR
RITONAVIR

Anatomical Therapeutic Chemical (ATC) code

(J05AE30) nirmatrelvir and ritonavir
nirmatrelvir and ritonavir

Medical condition to be studied

COVID-19
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

1000
Study design details

Study design

Retrospective observational study

Main study objective

To describe real-world safety of nirmatrelvir/ritonavir among patients treated with nirmatrelvir/ritonavir in China.

Outcomes

Incidence of AEs and SAEs with explicit attribution to nirmatrelvir/ritonavir, Proportion of patients with nirmatrelvir/ritonavir dose change due to AEs with explicit attribution to nirmatrelvir/ritonavir, Proportion of patients experiencing safety related scenarios; Treatment patterns endpoints include proportion and/or duration of nirmatrelvir/ritonavir, and/or concomitant COVID-19-related treatments, or other concomitant treatments. Effectiveness endpoints include COVID-19 disease severity progressed or death, time to alleviation of signs/symptoms, Proportion of patients with consecutive negative tests and time to first negative test.

Data analysis plan

This study is descriptive in nature and no formal hypothesis testing will be conducted. Continuous variables will be summarized using n, mean, median, minimum, maximum, standard deviation (SD), and 25th and 75th percentiles, and in addition, 95% CI will be provided for effectiveness variables. Categorical variables will be summarized using number and percentages of each category. For continuous and categorical variables, missing data will not be imputed and will be reported as frequency and percentage. Missing data will not be included in the summary statistics. For time-to-event variables (such as time to alleviation of all targeted COVID-19 signs and symptoms), Kaplan Meier (K-M) plots will be generated, and median time will be estimated along with the corresponding 95% CI.
Documents
Study report
English (805.02 KB - PDF)View document
English (400.64 KB - PDF)View document